Overview
The programme of research in the Tumour Angiogenesis Group aims to understand how the process of tumour vascularisation is controlled and it can be targeted effectively to treat cancer.
In breast cancer, and other solid cancers, it is well recognised that tumour vascularisation is required for tumour growth. Tumour vascularisation may occur through several mechanisms including: tumour angiogenesis, tumour co-option of existing vessels or tumour recruitment of endothelial progenitor cells. Tumour angiogenesis is driven by pro-angiogenic growth factors which signal directly to endothelial cells. Several angiogenesis inhibitors which target these signals are currently being tested in cancer patients. Although these agents can extend progression free-survival, many tumours are refractory or acquire resistance to this form of therapy. We therefore need a better understanding of tumour vascularisation and angiogenesis inhibitors in order to develop more effective treatments for breast and other cancers.
Our focus
In our laboratory, we are focused on understanding how growth factors control the process of tumour angiogenesis, understanding how angiogenesis inhibitors work and developing new treatment strategies for targeting the vasculature of tumours.
